What is Pi-Cardia?
Pi-Cardia is a pioneering medical device enterprise dedicated to transforming the treatment of aortic stenosis through advanced engineering. The company has developed a novel, low-profile catheter system designed to address valve calcifications with precision. By utilizing a proprietary mechanical impact mechanism, the technology effectively creates fractures in calcified tissue while meticulously preserving the integrity of surrounding soft tissue. This innovation represents a significant shift in how clinicians approach structural heart disease, offering a less invasive alternative to traditional surgical interventions. Positioned at the intersection of biotechnology and mechanical engineering, Pi-Cardia is actively addressing substantial unmet needs in the global cardiology market.
How much funding has Pi-Cardia raised?
Pi-Cardia has raised a total of $10M across 1 funding round:
Private Equity
$10M
Private Equity (2016): $10M with participation from Innogest and Clal Biotechnology Industries Ltd.
Key Investors in Pi-Cardia
Innogest
Innogest Capital is an investment firm that focuses on partnering with entrepreneurial visionaries to support companies that create significant impact, specializing in technology and healthcare sectors.
Clal Biotechnology Industries Ltd.
Clal Biotechnology Industries is a leading Israeli life sciences investment company that specializes in identifying and nurturing innovative ventures that develop proprietary solutions to address unmet medical needs.
What's next for Pi-Cardia?
With the recent capital injection, Pi-Cardia is poised to enter a pivotal phase of its growth trajectory. The strategic focus will likely shift toward expanding clinical trial data and navigating the complex regulatory pathways required for broader market adoption. By leveraging the expertise of its institutional partners, the company is expected to optimize its manufacturing processes and prepare for commercialization. The long-term objective remains the establishment of its catheter technology as a standard-of-care solution for patients suffering from aortic stenosis, ultimately driving value for both healthcare providers and stakeholders in the life sciences sector.
See full Pi-Cardia company page
